Biocytogen and BeOne Medicines Sign Antibody Licensing Agreement to Boost Cancer Treatment Innovations

Biocytogen and BeOne Medicines’ Licensing Agreement

Image Credits: Biocytogen

Announcement

Biocytogen [Pharmaceuticals Co., Ltd., a leading biotechnology company that excels in research and development of antibody-based drugs with its innovative technologies] has signed a licensing agreement with BeOne Medicines Ltd., an oncology company specializing in the development of full human antibodies. Earlier to this licensing agreement, BeOne Medicines had received a license to use BioCytogen’s RenMice®, a full human antibody platform. To this development, the new agreement will help expand the partnership in the antibody license. It will power the professional relationship between the two prestigious companies.

Contribution to the Healthcare Market

Both companies have been excellent in their respective areas, introducing remarkable efforts in the healthcare sector. The partnership will reshape the healthcare market and elevate expectations to bring innovation to the sector. Biocytogen’s gene editing technology has already accelerated the genetically processed proprietary RenMice®, which is a successful effort. Whereas, BeOne Medicines has been growing in its oncology field, mainly in solid tumors and hematologic cancers.

The company’s major focus is on providing an affordable cancer treatment to patients. A recent advancement of BRUKINSA (Zanubrutinib) and the development of sonrotoclax is a valuable contribution to the healthcare market. Together, these companies will strengthen the study and expand the solution on which they have collaborated. Healthcare industries have been fueled by new technologies, engagements, partnerships, and acquisitions, which rank this market at the top globally. Regions are covering a vast range of discoveries and are still exploring the best for the market. Further, the agreement elaborates on the financial distribution of the profit and other respective conditions.

Agreement

Under the terms and conditions of the agreement, the biocytogen company will receive an upfront payment from Beone Medicines. Also, Biocytogen will be declared eligible to receive regulatory and development profit payments. Additionally, Biocytogen will also be receiving tiered royalties and commercial milestone payments if there’s a profit in the net sales of the licensed products.

Views and Statements

President and CEO of Biocytogen, Dr. Yuelei Shuen, said, “BeOne medicines are popular for their drug development, and we are excited for this collaboration. Under this agreement, the antibodies were finely discovered by using our proprietary RenMice®, a full human antibody platform. This showcases our potential to encourage partners in leading innovative drug discovery. We are waiting for these molecules to progress in continuity into the treatment and clinics, providing various innovative treatment options to patients globally.”